<DOC>
	<DOCNO>NCT01762449</DOCNO>
	<brief_summary>The primary intent study add body knowledge scleroderma patient interstitial lung disease . While lung disease recognize leading cause death amongst patient scleroderma , large body literature describe long-term morbidity mortality rate scleroderma patient . For reason , investigator follow participant Scleroderma Lung Study ( NCT00004563 ) participation study conclude . In addition , investigator assess subject receive one year oral cyclophosphamide Scleroderma Lung Study experience progression scleroderma-related lung disease follow end study .</brief_summary>
	<brief_title>Morbidity Mortality Follow Up Scleroderma Lung Study</brief_title>
	<detailed_description>Retrospective prospective data collect patient participate Scleroderma Lung Study ( SLS ) . An attempt make include participant Scleroderma Lung Study , report alive end study . A total 158 subject ( 79 per treatment arm ) randomize original Scleroderma Lung Study . Of , 109 subject complete study . A single telephone interview participant assess occurrence severe event review participant 's medical record may conduct . The outcome information combine information collect participant SLS study . The data collect include information mortality , development cancer , development organ failure , performance status .</detailed_description>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Participation Scleroderma Lung Study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Scleroderma</keyword>
	<keyword>interstitial lung disease</keyword>
</DOC>